Delcath Systems (NASDAQ: DCTH) recently received a number of ratings updates from brokerages and research firms:
- 11/14/2026 – Delcath Systems was upgraded by Wall Street Zen from “buy” to “strong-buy”.
- 11/12/2026 – Delcath Systems was upgraded by Weiss Ratings from “hold (c-)” to “hold (c+)”.
- 11/11/2026 – Delcath Systems was upgraded by Zacks Research from “hold” to “strong-buy”.
- 11/10/2026 – Delcath Systems had its price target raised by HC Wainwright from $32.00 to $36.00. They now have a “buy” rating on the stock.
- 11/9/2026 – Delcath Systems had its price target raised by BTIG Research from $21.00 to $25.00. They now have a “buy” rating on the stock.
- 10/28/2026 – Delcath Systems was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
- 10/13/2026 – Delcath Systems was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
- 10/6/2026 – Delcath Systems was downgraded by Zacks Research from “strong-buy” to “hold”.
- 9/28/2026 – Delcath Systems was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
Delcath Systems Stock Performance
Shares of Delcath Systems stock opened at $19.87 on Tuesday. The stock has a 50 day moving average of $15.95 and a 200 day moving average of $12.75. The firm has a market capitalization of $691.28 million, a price-to-earnings ratio of 124.19 and a beta of 0.62. Delcath Systems, Inc. has a fifty-two week low of $8.12 and a fifty-two week high of $22.51.
Delcath Systems (NASDAQ:DCTH – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.26. Delcath Systems had a return on equity of 5.56% and a net margin of 6.05%. The company had revenue of $35.10 million for the quarter, compared to the consensus estimate of $25.99 million. Analysts forecast that Delcath Systems, Inc. will post 0.13 EPS for the current year.
Insider Activity
In related news, Director Bridget A. Martell sold 22,500 shares of the business’s stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $21.71, for a total value of $488,475.00. Following the sale, the director directly owned 22,500 shares in the company, valued at approximately $488,475. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 19.36% of the company’s stock.
Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.
Read More
- Five stocks we like better than Delcath Systems
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Delcath Systems Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems Inc and related companies with MarketBeat.com's FREE daily email newsletter.
